Top

Published in:

01-11-2013 | Research Article

Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer

Authors: P. J. Vlachostergios, I. Gioulbasanis, S. Ghosh, C. Tsatsanis, G. Papatsibas, A. Xyrafas, E. Hatzidaki, C. Vasiliou, K. Kamposioras, S. Agelaki, A. N. Margioris, D. Nasi, V. Georgoulias, C. N. Papandreou

Published in: Clinical and Translational Oncology | Issue 11/2013

Abstract

Objective

Cancer patients usually develop malnutrition which may alter their innate immune system integrity. The aim of this study was to investigate the clinical relevance of chemokine response after lipopolysaccharide (LPS)-stimulation in metastatic non-small cell lung cancer (NSCLC).

Methods

Blood samples from metastatic NSCLC patients were incubated with LPS before the onset of systemic therapy. Interleukin (IL)-6 and IL-8 levels at baseline and after LPS-stimulation were measured and the fold change compared to baseline levels was evaluated as the stimulation index for each cytokine per patient. Results were correlated with sex, age, smoking status, histologic subtype, performance status (PS), albumin, Mini Nutritional Assessment (MNA) status and clinical outcomes.

Results

Totally 103 patients were evaluated. Mean (±SD) stimulation index was 37.6 (±57.8) for IL-6 and 76.7 (±133.4) for IL-8. The disease control rate after first-line chemotherapy was 44/80 (55 %) and the mean (±SD) progression-free survival (PFS) and overall survival (OS) were 4.2 (±3.9) and 9.2 (±1.1) months, respectively. MNA, PS, albumin, IL-6 and IL-8 stimulation indices were univariately associated with PFS and OS. IL-8 stimulation index emerged as an independent predictor of both PFS and OS, along with PS, and albumin levels.

Conclusion

The extent of IL-6 and IL-8 stimulation after ex vivo induction with LPS is an important predictor of clinical outcome in metastatic NSCLC patients.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.PubMedCrossRef

Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004;40:1660–7.PubMedCrossRef

Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancer’s inflammatory roots. Clin Cancer Res. 2011;17:6125–9.PubMedCrossRef

Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138–46.PubMedCrossRef

Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol. 2010;26:146–51.PubMedCrossRef

Wang J, Huang M, Lee P, Komanduri K, Sharma S, Chen G, et al. Interleukin-8 inhibits non-small cell lung cancer proliferation: a possible role for regulation of tumor growth by autocrine and paracrine pathways. J Interferon Cytokine Res. 1996;16:53–60.PubMedCrossRef

Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011;103:1112–22.PubMedCrossRef

Gioulbasanis I, Patrikidou A, Kitikidou K, Papadimitriou K, Vlachostergios PJ, Tsatsanis C, et al. Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosis. Nutr Cancer. 2012;64:41–7.PubMedCrossRef

Fortunati N, Manti R, Birocco N, Pugliese M, Brignardello E, Ciuffreda L, et al. Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol Rep. 2007;18:1521–7.PubMed

10.

Yannelli JR, Tucker JA, Hidalgo G, Perkins S, Kryscio R, Hirschowitz EA. Characteristics of PBMC obtained from leukapheresis products and tumor biopsies of patients with non-small cell lung cancer. Oncol Rep. 2009;22:1459–71.PubMedCrossRef

11.

Dahlke E, Schlag R, Langenmayer I, Frankenberger M, Käfferlein E, Subkowski T, et al. Decreased production of TNF and IL-6 in whole blood of CLL patients. Am J Hematol. 1995;49:76–82.PubMedCrossRef

12.

Suzuki K, Koyama T, Kobayashi S, Kobayashi K, Inagaki K, Abe Y, et al. Novel method for detection of ex vivo tumor necrosis factor alpha production by monocytes. J Clin Lab Anal. 2002;16:273–8.PubMedCrossRef

13.

Berthier F, Lambert C, Genin C, Bienvenu J. Evaluation of an automated immunoassay method for cytokine measurement using the Immulite 400 Immunoassay system. Clin Chem Lab Med. 1999;37:593–9.PubMedCrossRef

14.

Vellas B, Guigoz Y, Garry PJ, Nourhashemi F, Bennahum D, Lauque S, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition. 1999;15:116–22.PubMedCrossRef

15.

Gioulbasanis I, Georgoulias P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, et al. Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis. Lung Cancer. 2011;74:516–20.PubMedCrossRef

16.

Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, Trivers G, et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev. 2009;18:215–22.PubMedCrossRef

17.

Su C, Zhou C, Zhou S, Xu J. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Med Oncol. 2011;28:1453–7.PubMedCrossRef

18.

Asselin-Paturel C, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, et al. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer. 1998;77:7–12.PubMedCrossRef

19.

Wei H, Sun R, Xiao W, Feng J, Zhen C, Xu X, et al. Type two cytokines predominance of human lung cancer and its reverse by traditional Chinese medicine TTMP. Cell Mol Immunol. 2004;1:63–70.PubMed

20.

Trejo YG, Bordenave RH, Beviacqua M, Zanoni L, Rumi LS. Tumor necrosis factor-alfa production by monocytes from lung and colorectal cancer patients. J Exp Clin Cancer Res. 2001;20:71–3.PubMed

21.

Trejo YG, Bordenave RH, Beviacqua M, Rumi LS. In vitro secretion of cytokines and prostaglandin-E2 by monocytes from lung cancer patients. Respir Med. 2001;95:243–5.PubMedCrossRef

22.

Miotto D, Boschetto P, Bononi I, Milani G, Legorini C, Cavallesco G, et al. CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer. Respir Med. 2007;101:1738–43.PubMedCrossRef

23.

Romagnani S. Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res. 1991;21:152–8.PubMedCrossRef

24.

Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187–91.PubMedCrossRef

25.

Parry SL, Sebbag M, Feldmann M, Brennan FM. Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha. J Immunol. 1997;158:3673–81.PubMed

26.

Kallio R, Surcel HM, Syrjälä H. Peripheral mononuclear cell IL-10 and IL-12 production is not impaired in patients with advanced cancer and severe infection. Cytokine. 2002;20:210–4.PubMedCrossRef

27.

Grandel U, Heygster D, Sibelius U, Fink L, Sigel S, Seeger W, et al. Amplification of lipopolysaccharide-induced cytokine synthesis in non-small cell lung cancer/neutrophil cocultures. Mol Cancer Res. 2009;7:1729–35.PubMedCrossRef

28.

Zhao L, Wang L, Ji W, Wang X, Zhu X, Hayman JA, et al. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan. Int J Radiat Oncol Biol Phys. 2009;74:1385–90.PubMedCrossRef

29.

Lu H, Zhu S, Qian L, Xiang D, Zhang W, Nie A, et al. Activated expression of the chemokine Mig after chemotherapy contributes to chemotherapy-induced bone marrow suppression and lethal toxicity. Blood. 2012;119:4868–77.PubMedCrossRef

30.

Hirota K, Oishi Y, Taniguchi H, Sawachi K, Inagawa H, Kohchi C, et al. Antitumor effect of inhalatory lipopolysaccharide and synergetic effect in combination with cyclophosphamide. Anticancer Res. 2010;30:3129–34.PubMed

Title: Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer
Authors: P. J. Vlachostergios
I. Gioulbasanis
S. Ghosh
C. Tsatsanis
G. Papatsibas
A. Xyrafas
E. Hatzidaki
C. Vasiliou
K. Kamposioras
S. Agelaki
A. N. Margioris
D. Nasi
V. Georgoulias
C. N. Papandreou
Publication date: 01-11-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 11/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1021-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2013

New sequencing technologies

Zoledronic acid in genitourinary cancer

Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer

Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?

VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer

Has discovery-based cancer research been a bust?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer